BBC Virtus LifeSci Biotech Clinical Trls ETF
LifeSci Biotech Clinical Trials USD

NAV as of 20-May-2022

19.8593

4 Week: 17.80 - 24.46

52 Week: 17.80 - 52.00

Latest Closing Price

19.81

Premium / Discount

-0.16

Expense Ratio

0.79%

Investment Objective

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

Main Fund Characteristics

Fund Manager:
Virtus
Asset Under Management:
14,909,531
Launch Date:
15/12/2014
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
180
Trading Currency:
USD
Style:
Small Blend
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
NYSE

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-48.593.64-13.33
1 Day1.260.000.00
1 Week1.218.880.14
1 Month-21.2921.63-0.98
3 Months-29.7030.38-0.98
6 Months-54.0438.40-1.41
1 Year-58.1842.83-1.36
2 Years-53.3656.47-0.94
3 Years-27.3970.85-0.39
5 Years-10.7883.58-0.13
10 Years0.000.000.00

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 0.00000.00000.00004.8732-36.548455.5596-17.497862.600430.8167-22.3478
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.000082.0000100.00001.000099.00001.000028.000099.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
N.A

Portfolio Data

Total Number of Holdings: 180

Number of Bond Holdings: 0

Number of Equity Holdings: 179

Total Market Value: 14,909,531

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Reata Pharmaceuticals Inc A2.67033,1380671,971
2Karyopharm Therapeutics Inc2.532244,9690637,211
3Achillion Pharmaceuticals Inc2.325692,0170585,228
4Ra Pharmaceuticals Inc2.255612,0770567,619
5Deciphera Pharmaceuticals Inc2.195111,9670552,397
6Immunogen Inc1.9243129,6520484,250
7Allakos Inc1.74176,1110438,281
8BeiGene Ltd ADR1.65342,1890416,063
9Krystal Biotech Inc1.61289,4320405,859
10Arrowhead Pharmaceuticals Inc1.56979,9420394,996

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant0.00
Large0.00
Medium2.60
Small16.49
Micro78.04

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

6.6195

Price/Book*

1.8293

Price/Sales*

2.0981

Price/Cash Flow*

4.2800

Dividend Yield*

0.0000

Growth Measures

Long-Term Earnings

2.5724

Historical Earnings

31.3920

Sales Growth

0.1192

Cash-Flow Growth

328.9233

Book-Value Growth

-0.0230

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.